1. A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk;Alden;Vet. Pathol.,2011
2. Barreyro, F.J., Holod, S., Finocchietto, P.V., Camino, A.M., Aquino, J.B., Avagnina, A., Carreras, M.C., Poderoso, J.J., Gores, G.J., (2014). The pan-caspase inhibitor Emricasan (emricasan) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. [Epub ahead of print].
3. Minocycline-induced black thyroid gland: medical curiosity or a marker for papillary cancer?;Birkedal;Curr. Surg.,2001
4. The caspase inhibitor emricasan attenuates hepatic injury and fibrosis in the bile duct ligated mouse;Canbay;J. Pharmacol. Exp. Ther.,2004
5. Fine-mapping CASP8 risk variants in breast cancer;Camp;Cancer Epidemiol. Biomark. Prev.,2012